CD33 and acute myeloid leukemia: In AML, a TriKe targeting the activating receptor NKG2C, the IL-15R, and the tumour-associated antigen CD33 showed potent NK-cell degranulation and cytokine production in response to primary CD33+ AML blasts [93].